We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Medtronic (MDT) Stock Sinks As Market Gains: Here's Why
Read MoreHide Full Article
In the latest close session, Medtronic (MDT - Free Report) was down 2.76% at $77.79. The stock fell short of the S&P 500, which registered a gain of 0.81% for the day. Meanwhile, the Dow experienced a rise of 0.73%, and the technology-dominated Nasdaq saw an increase of 1.03%.
Heading into today, shares of the medical device company had lost 9.25% over the past month, lagging the Medical sector's loss of 0.96% and the S&P 500's gain of 9.47%.
The upcoming earnings release of Medtronic will be of great interest to investors. The company's earnings report is expected on June 3, 2026. The company's earnings per share (EPS) are projected to be $1.58, reflecting a 2.47% decrease from the same quarter last year. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $9.66 billion, up 8.22% from the year-ago period.
MDT's full-year Zacks Consensus Estimates are calling for earnings of $5.57 per share and revenue of $36.15 billion. These results would represent year-over-year changes of +1.46% and +7.78%, respectively.
Additionally, investors should keep an eye on any recent revisions to analyst forecasts for Medtronic. These recent revisions tend to reflect the evolving nature of short-term business trends. Consequently, upward revisions in estimates express analysts' positivity towards the business operations and its ability to generate profits.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. To exploit this, we've formed the Zacks Rank, a quantitative model that includes these estimate changes and presents a viable rating system.
The Zacks Rank system, ranging from #1 (Strong Buy) to #5 (Strong Sell), possesses a remarkable history of outdoing, externally audited, with #1 stocks returning an average annual gain of +25% since 1988. Within the past 30 days, our consensus EPS projection has moved 0.04% lower. Medtronic is holding a Zacks Rank of #4 (Sell) right now.
From a valuation perspective, Medtronic is currently exchanging hands at a Forward P/E ratio of 12.87. This represents a discount compared to its industry average Forward P/E of 18.37.
Meanwhile, MDT's PEG ratio is currently 1.86. Comparable to the widely accepted P/E ratio, the PEG ratio also accounts for the company's projected earnings growth. As of the close of trade yesterday, the Medical - Products industry held an average PEG ratio of 1.65.
The Medical - Products industry is part of the Medical sector. This group has a Zacks Industry Rank of 157, putting it in the bottom 36% of all 250+ industries.
The Zacks Industry Rank is ordered from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Remember to apply Zacks.com to follow these and more stock-moving metrics during the upcoming trading sessions.
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
Medtronic (MDT) Stock Sinks As Market Gains: Here's Why
In the latest close session, Medtronic (MDT - Free Report) was down 2.76% at $77.79. The stock fell short of the S&P 500, which registered a gain of 0.81% for the day. Meanwhile, the Dow experienced a rise of 0.73%, and the technology-dominated Nasdaq saw an increase of 1.03%.
Heading into today, shares of the medical device company had lost 9.25% over the past month, lagging the Medical sector's loss of 0.96% and the S&P 500's gain of 9.47%.
The upcoming earnings release of Medtronic will be of great interest to investors. The company's earnings report is expected on June 3, 2026. The company's earnings per share (EPS) are projected to be $1.58, reflecting a 2.47% decrease from the same quarter last year. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $9.66 billion, up 8.22% from the year-ago period.
MDT's full-year Zacks Consensus Estimates are calling for earnings of $5.57 per share and revenue of $36.15 billion. These results would represent year-over-year changes of +1.46% and +7.78%, respectively.
Additionally, investors should keep an eye on any recent revisions to analyst forecasts for Medtronic. These recent revisions tend to reflect the evolving nature of short-term business trends. Consequently, upward revisions in estimates express analysts' positivity towards the business operations and its ability to generate profits.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. To exploit this, we've formed the Zacks Rank, a quantitative model that includes these estimate changes and presents a viable rating system.
The Zacks Rank system, ranging from #1 (Strong Buy) to #5 (Strong Sell), possesses a remarkable history of outdoing, externally audited, with #1 stocks returning an average annual gain of +25% since 1988. Within the past 30 days, our consensus EPS projection has moved 0.04% lower. Medtronic is holding a Zacks Rank of #4 (Sell) right now.
From a valuation perspective, Medtronic is currently exchanging hands at a Forward P/E ratio of 12.87. This represents a discount compared to its industry average Forward P/E of 18.37.
Meanwhile, MDT's PEG ratio is currently 1.86. Comparable to the widely accepted P/E ratio, the PEG ratio also accounts for the company's projected earnings growth. As of the close of trade yesterday, the Medical - Products industry held an average PEG ratio of 1.65.
The Medical - Products industry is part of the Medical sector. This group has a Zacks Industry Rank of 157, putting it in the bottom 36% of all 250+ industries.
The Zacks Industry Rank is ordered from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Remember to apply Zacks.com to follow these and more stock-moving metrics during the upcoming trading sessions.